{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:29:58Z","timestamp":1790627398920,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.clml.2024.04.004","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T02:13:56Z","timestamp":1713492836000},"page":"604-610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Changes in income and employment after diagnosis among patients with multiple myeloma in The Netherlands"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8700-8598","authenticated-orcid":false,"given":"Christine","family":"Bennink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirian","family":"Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia F.A.","family":"Duijts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Scheurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedwig M.","family":"Blommestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.04.004_bib0001","first-page":"14","article-title":"Het multipel myeloom in Nederland, 2014-2017","volume":"2020","author":"Brink","year":"2020","journal-title":"Integraal Kankercentrum Nederland (IKNL)"},{"issue":"11","key":"10.1016\/j.clml.2024.04.004_bib0002","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41408-021-00571-8","article-title":"Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study","volume":"11","author":"Brink","year":"2021","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.clml.2024.04.004_bib0003","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5144\/0256-4947.2021.198","article-title":"Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia","volume":"41","author":"Abdrabou","year":"2021","journal-title":"Ann Saudi Med"},{"issue":"6","key":"10.1016\/j.clml.2024.04.004_bib0004","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.clml.2024.04.004_bib0005","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2024.04.004_bib0006","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-021-00548-7","article-title":"The effect of duration of lenalidomide maintenance and outcomes of different salvage regimens in patients with multiple myeloma (MM)","volume":"11","author":"Ho","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.clml.2024.04.004_bib0007","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.clml.2024.04.004_bib0008","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s11764-013-0300-z","article-title":"Type of hematological malignancy is crucial for the return to work prognosis: a register-based cohort study","volume":"7","author":"Horsboel","year":"2013","journal-title":"J Cancer Surviv"},{"issue":"12","key":"10.1016\/j.clml.2024.04.004_bib0009","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1038\/s41409-021-01429-0","article-title":"Predictors of return to work after autologous stem cell transplantation in patients with multiple myeloma","volume":"56","author":"Granell","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"10.1016\/j.clml.2024.04.004_bib0010","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/ejh.13298","article-title":"Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy","volume":"103","author":"Jackson","year":"2019","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2024.04.004_bib0011","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3109\/0284186X.2013.875625","article-title":"Risk of disability pension for patients diagnosed with haematological malignancies: a register-based cohort study","volume":"53","author":"Horsboel","year":"2014","journal-title":"Acta Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.04.004_bib0012","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ejh.12876","article-title":"Economic burden of relapsed or refractory multiple myeloma: results from an international trial","volume":"99","author":"Robinson","year":"2017","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.04.004_bib0013","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1186\/s12885-020-07028-4","article-title":"The patient-level effect of the cost of Cancer care - financial burden in German Cancer patients","volume":"20","author":"Mehlis","year":"2020","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.clml.2024.04.004_bib0014","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/0284186X.2016.1266083","article-title":"Sustained employability and health-related quality of life in cancer survivors up to four years after diagnosis","volume":"56","author":"Duijts","year":"2017","journal-title":"Acta Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.04.004_bib0015","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.1007\/s00520-020-05719-z","article-title":"Financial toxicity and employment status in cancer survivors. A systematic literature review","volume":"28","author":"Mols","year":"2020","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.clml.2024.04.004_bib0016","doi-asserted-by":"crossref","first-page":"e13481","DOI":"10.1111\/ecc.13481","article-title":"Perspectives on returning to work of multiple myeloma patients: a qualitative interview study","volume":"30","author":"Bennink","year":"2021","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"1","key":"10.1016\/j.clml.2024.04.004_bib0017","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1080\/13696998.2022.2133823","article-title":"Beyond medicines' barriers: exploring the true cost of multiple myeloma","volume":"25","author":"Choon-Quinones","year":"2022","journal-title":"J Med Econ"},{"issue":"10","key":"10.1016\/j.clml.2024.04.004_bib0018","first-page":"1019","article-title":"Costs Associated with productivity loss among U.S. patients newly diagnosed with multiple myeloma receiving oral versus injectable chemotherapy","volume":"24","author":"Merola","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"10.1016\/j.clml.2024.04.004_bib0019","doi-asserted-by":"crossref","first-page":"454","DOI":"10.4149\/neo_2021_201103N1173","article-title":"Economic aspects of multiple myeloma: real costs associated with disease in the Slovak Republic","volume":"68","author":"Babela","year":"2021","journal-title":"Neoplasma"},{"key":"10.1016\/j.clml.2024.04.004_bib0020","unstructured":"IKNL. Netherlands Cancer Registry (NCR): IKNL; 2023 [cited 2023. Available from: https:\/\/iknl.nl\/en\/ncr."},{"key":"10.1016\/j.clml.2024.04.004_bib0021","unstructured":"World Health Organization. International Classification of Diseases for Oncology. 2013."},{"key":"10.1016\/j.clml.2024.04.004_bib0022","unstructured":"LLC S, inventorStata Statistical Software: Release 162019."},{"key":"10.1016\/j.clml.2024.04.004_bib0023","unstructured":"Microsoft Coorporation. Microsoft Excel 2018 [Available from: https:\/\/office.microsoft.com\/excel."},{"issue":"4","key":"10.1016\/j.clml.2024.04.004_bib0024","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/NCC.0b013e3182693522","article-title":"Personal financial effects of multiple myeloma and its treatment","volume":"36","author":"Goodwin","year":"2013","journal-title":"Cancer Nurs"},{"issue":"3","key":"10.1016\/j.clml.2024.04.004_bib0025","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.gaceta.2015.01.010","article-title":"Productivity loss due to premature mortality caused by blood cancer: a study based on patients undergoing stem cell transplantation","volume":"29","author":"Ortega-Ortega","year":"2015","journal-title":"Gac Sanit"},{"issue":"4","key":"10.1016\/j.clml.2024.04.004_bib0026","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ijc.33826","article-title":"Paid and unpaid productivity losses due to premature mortality from cancer in Europe in 2018","volume":"150","author":"Ortega-Ortega","year":"2022","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.clml.2024.04.004_bib0027","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clml.2018.01.006","article-title":"Assessing the effect of adherence on patient-reported outcomes and out of pocket costs among patients with multiple myeloma","volume":"18","author":"Gupta","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10.1016\/j.clml.2024.04.004_bib0028","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1016\/S2352-3026(15)00151-9","article-title":"Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study","volume":"2","author":"Huntington","year":"2015","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.clml.2024.04.004_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-064714","article-title":"Impact of cancer on income, wealth and economic outcomes of adult cancer survivors: a scoping review","volume":"12","author":"Bentley","year":"2022","journal-title":"BMJ Open"},{"issue":"13","key":"10.1016\/j.clml.2024.04.004_bib0030","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.ejca.2011.11.030","article-title":"Socio-economic implications of cancer survivorship: results from the PROFILES registry","volume":"48","author":"Mols","year":"2012","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.clml.2024.04.004_bib0031","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.jval.2021.05.002","article-title":"Measurement instruments of productivity loss of paid and unpaid work: a systematic review and assessment of suitability for health economic evaluations from a societal perspective","volume":"24","author":"Hubens","year":"2021","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.clml.2024.04.004_bib0032","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jval.2022.06.015","article-title":"Analyzing, and presenting work productivity loss in randomized controlled trials: a scoping review","volume":"26","author":"Zhang","year":"2023","journal-title":"Value Health"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T04:27:25Z","timestamp":1724473645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024001526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2152265024001526"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.04.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in income and employment after diagnosis among patients with multiple myeloma in The Netherlands","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}